Lara McGrath

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Tina Cascone, Gozde Kar, Jonathan Spicer et al. · Cancer Discovery · 2023 · 117 citations · Full text

Pharmacy, Oncology, Pharmacology +17

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Jessica D. Weaver, Edward C. Stack, Joshua Buggé et al. · OncoImmunology · 2022 · 58 citations · Full text

Life Sciences, Immunology, Oncology +17

De novo transcriptome assembly for the lobster Homarus americanus and characterization of differential gene expression across nervous system tissues

Lara McGrath, Steven V. Vollmer, Stefan T. Kaluziak et al. · BMC Genomics · 2016 · 36 citations · Full text

Life Sciences, Biology, Neuroscience +17

Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors

Ben Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith et al. · Molecular Cancer Therapeutics · 2023 · 34 citations

Medicine, Immunology, Oncology +17